Convelo Therapeutics
Cleveland, US · Delaware corporation · 3 known investors
Find your way into Convelo Therapeutics
1,227 people in our graph share verified history with the Convelo Therapeutics team — schools, employers, funds. One of them is your warm intro.
Crystal Huangunlockedknows Drew Adams · together at Harvard University (overlapped)
×3knows the team · via Harvard University
×5knows the team · via University of Oxford
knows the team · via Boston Children's Hospital
×2knows the team · via Case Western Reserve University
Convelo Therapeutics develops remyelination-enhancing therapies that target the central nervous system's myelination pathway to repair nerve damage in people with multiple sclerosis. The company operates a drug discovery platform focused on neurological disorders and originated from research at Case Western Reserve University.
Founders & leadership
PT
Paul TesarinCo-founder (Professor, PhD)A translational neuroscientist at Case Western Reserve University School of Medicine where he holds the Pavey Family Eminent Professor position and directs the Institute for Glial Sciences, Tesar has developed stem cell and drug-discovery platforms focused on oligodendrocytes that have generated therapeutic programs for neurological diseases including multiple sclerosis and Pelizaeus-Merzbacher disease; he is co-founder and President of Convelo Therapeutics.
DA
Drew AdamsinCo-founder (Professor, PhD)Drew Adams is a chemistry PhD from Harvard and postdoctoral researcher in cell-based assay development at the Broad Institute who joined Case Western Reserve University in 2015 as a professor studying cholesterol pathway targets in myelin biology. He co-founded Convelo Therapeutics in 2017 to translate his research into remyelination therapies for multiple sclerosis and related myelin disorders.
DR
Derrick RossiinLeader/ExecutiveDerrick Rossi is a stem cell scientist and biotech executive who previously held academic positions as an Associate Professor at Harvard Medical School and investigator at Boston Children's Hospital, focusing on stem cell biology and regenerative medicine. He earned his BSc and MSc from the University of Toronto and PhD from the University of Helsinki, and has co-founded multiple biotechnology companies including Moderna, Intellia Therapeutics, Magenta Therapeutics, and Stelexis Therapeutics; he currently leads Convelo Therapeutics as CEO.
TS
Tracy SaxtoninChief Operating Officer
EM
Ed MokHead of Finance
SS
Samantha StubblefieldinVP of Operations and Business DevelopmentSamantha Stubblefield holds a PhD in Molecular Biology from Case Western Reserve University and a B.S. in Biology from the University of Akron. She has worked in drug discovery across retinal, neurological, and inflammatory disorders, including roles as a senior scientist at Athersys (a stem cell therapy company focused on clinical development), and at the Harrington Discovery Institute supporting academic drug discovery programs toward commercialization; she now leads discovery efforts at Convelo Therapeutics and manages research partnerships including work with Genentech.
RR
Ronald RichardNamed on SEC filing
BS
Bill SanfordNamed on SEC filing
SL
Steven LandauNamed on SEC filing
Investors · 3
Reported raises · per SEC filings
Form D private placements$12.8M disclosed across 2 rounds · 2017–2022
▶$10.8MraisedDec 2022 · 1 investors · Other Health CareRule 506(b)
▶$10.8MraisedDec 2022 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Drew AdamsDirector
- Ronald RichardDirector
- Paul TesarDirector
- Derrick RossiDirector
- Bill SanfordDirector
- Offering amount
- $12M
- Amount sold
- $10.8M
- Minimum investment
- $50K
- Proceeds to insiders
- $400K
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedDec 2017 · 1 investors · Other Health CareRule 506(b)
▶$2MraisedDec 2017 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Drew AdamsDirector
- Paul TesarDirector
- Ronald RichardDirector
- Bill SanfordDirector
- Derrick RossiExecutive Officer, Director
- Steven LandauExecutive Officer
- Offering amount
- $15M
- Amount sold
- $2M
- First sale
- Nov 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Convelo Therapeutics do?
- Convelo Therapeutics develops remyelination-enhancing therapies that target the central nervous system's myelination pathway to repair nerve damage in people with multiple sclerosis. The company operates a drug discovery platform focused on neurological disorders and originated from research at Case Western Reserve University.
- Who founded Convelo Therapeutics?
- Convelo Therapeutics was founded by Paul Tesar, Drew Adams.
- Who are Convelo Therapeutics's investors?
- Convelo Therapeutics's investors include CWRU Technology Ventures, JobsOhio Ventures, Jumpstart Ventures.
- How much funding has Convelo Therapeutics raised?
- Convelo Therapeutics has disclosed $12.8M raised across 2 rounds.
- Where is Convelo Therapeutics headquartered?
- Convelo Therapeutics is headquartered in Cleveland, US.